Answers are grounded in this paper and cite their sources.
Immune checkpoint inhibitors (ICI) are are now widely used for solid tumours and has improved outcomes for patients with malignant disease. However, despite these improved outcomes, acute kidney injury (AKI) and electrolyte disorder has emerged as an important adverse effects of ICI.
No takes yet. Share an insight, caveat, or question.
Nilasari et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: